Joshua Sabari, MD

@OncLive @BalazsHalmosMD @ae_cancercenter @MontefioreNYC Did you see the recent data for front line Zongertinib in HER2 Exon 20 mutation positive NSCLC? nejm.org/doi/full/10.10… what would you recommend in the front line setting? What are the unmet needs in the HER2 exon 20 space? @Exon20Group

Don't just search any burning questions you have about lung cancer and the broader oncology field; drop them in the comments of this post, and @BalazsHalmosMD, of @ae_cancercenter and @MontefioreNYC, will answer them in OncLive's new #AskMeAnything series! 👀 From the latest in targeted therapies, to immunotherapy combinations, to navigating resistance mechanisms, NOTHING is off the table! 🔬 Drop your questions in the comments section of this post by April 16th! ‼️ #lcsm #oncology #cancer #medtwitter

@Aiims1742 @NEJM @Perlmutter_CC Huge team effort. We thank our patients and their families for enrolling on this trial and moving the field forward. There is still a lot of work to be done. @Exon20Group

First line oral targeted therapy for advanced non small cell lung cancer, including responses observed in dreaded brain metastatic disease (thanks to the chemistry behind Zongertinib crossing BBB). New study in @NEJM nejm.org/doi/full/10.10… @JSabari @Perlmutter_CC

@IDEOlogyHealth Permitting NGS results do not identify oncogenic drivers or co-mutations that would favor alternative approaches (i.e., non IO, TKI instead).

@IDEOlogyHealth Or not

@IDEOlogyHealth Or a CR

IDEO Xchange: In resectable NSCLC, which clinical factors most often lead you to use a perioperative chemo‑IO approach rather than neoadjuvant IO/chemo alone?

@NarjustFlorezMD @IDEOlogyHealth I’m learning from you

@JSabari @IDEOlogyHealth He typed something!!!

IDEO Xchange: How would you sequence HER2-directed therapies in a patient with mNSCLC?

@IDEOlogyHealth I agree with @lungoncdoc nuanced discussion, we need to change the discussion from treatment intensification to who should be offer de-escalation because standard of care is now combination therapy

IDEO Xchange: What’s your preferred approach to treatmentintensification for 1L EGFR+ NSCLC?

You are invited to learn about Lung Cancer Treatment Breakthroughs at @Perlmutter_CC @nyulangone Thursday December 11, 2025 6-7PM EST @StermanDaniel, Benjamin Cooper, Harvey Pass, Abraham Chachoua. i.nyulangone.org/vl6

@chulkimMD @LombardiCancer @StephenVLiu Congrats!

Honored to step into the role of Director of Thoracic Oncology. Big shoes to fill following Dr. Liu’s leadership. Grateful for the trust and support - excited to work with this amazing team to provide the best care and drive cutting-edge research @LombardiCancer @StephenVLiu

FDA approval for lung cancer med Hernexeos fiercepharma.com/pharma/boehrin… @Perlmutter_CC @nyulangone @EGFRResisters @Exon20Group

Zongertinib (oral TKI) now @US_FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2+: - 71% ORR w/ 14.1mos mDoR - mPFS 12.4% - ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash #OncTwitter #MedTwitter

FDA approves zongertinib 120mg po daily for previously treated advanced #HER2 NSCLC. In the phase 1b Beamion-LUNG 1 study @NEJM, RR 71% (42% post ADC), DOR 14.1m, intracranial RR 41%. Main toxicity is diarrhea (56%, 48% grade 1), no ILD. fda.gov/drugs/resource…

#FDA grants accelerated approval to a treatment for non-small cell lung cancer. fda.gov/drugs/resource…

Proud to work here @nyulangone @Perlmutter_CC

Honored to be an Expert Judge Mentor for #EGFRSummit! Submit your abstracts by 8/8 to be part of the next class of @EGFRSummit Young Investigators! ➡️ ce.ceconcepts.com/EGFR2025CFA #EGFR #LCSM #MedTwitter #MedEd

Discussing data hot off the press here at #HawaiiLung25. Dr. Joshua Sabari reviews the latest FDA approval of DatoDXd for our patients with EGFR+ mNSCLC.